GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Common Stock

Radiopharm Theranostics (Radiopharm Theranostics) Common Stock : $66.30 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Common Stock?

Radiopharm Theranostics's quarterly common stock increased from Dec. 2022 ($64.57 Mil) to Jun. 2023 ($65.26 Mil) and increased from Jun. 2023 ($65.26 Mil) to Dec. 2023 ($66.30 Mil).

Radiopharm Theranostics's annual common stock increased from . 20 ($0.00 Mil) to Jun. 2022 ($60.97 Mil) and increased from Jun. 2022 ($60.97 Mil) to Jun. 2023 ($65.26 Mil).


Radiopharm Theranostics Common Stock Historical Data

The historical data trend for Radiopharm Theranostics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Common Stock Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Common Stock
60.97 65.26

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock 61.47 60.97 64.57 65.26 66.30

Radiopharm Theranostics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022